Latest news with #OtsukaPharmaceutical
Medscape
a day ago
- Health
- Medscape
FDA Panel Rejects Combo Drug for PTSD
An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti, Otsuka Pharmaceutical Co., Ltd.), in combination with the selective serotonin reuptake inhibitor (SSRI) sertraline, for the treatment of adults with posttraumatic stress disorder (PTSD). Based on the data at hand, in a 10 to 1 vote, the Psychopharmacologic Drugs Advisory Committee felt that the efficacy of brexpiprazole, when started concurrently with sertraline, has not been established in PTSD. In a briefing document released ahead of the FDA committee meeting, FDA reviewers flagged 'discordant' results from the two phase 3 trials. They noted that while study '071' was 'robustly positive,' study '072' was 'clearly and convincingly' negative and failed to demonstrate statistical significance on its primary or secondary endpoints. Given the conflicting phase 3 results, the company also provided the FDA with data from the '061' phase 2 study. However, the reviewers cited statistical and methodologic concerns with this study. The data from this study were 'retrospectively analyzed with post hoc multiplicity control methods to provide additional efficacy evidence, raising concerns about type I error inflation,' the reviewers cautioned. The committee also had concerns about the 061 data analysis. Taken together, the data 'is not crossing that bar in my head,' said committee member Jess Fiedorowicz, MD, PhD, head of the Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada. Walter Dunn, MD, PhD, director, Mood Disorders Section, West Los Angeles Veterans Affairs Medical Center, Los Angeles, agreed. Dunn said while he is a 'strong advocate' for increasing treatment options for PTSD, he was 'not convinced' of the efficacy of the combination given the conflicting data. Murray Raskind, MD, professor, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, felt it would be 'hard to translate the confusing contradictory datasets to my clinical practice.' Raskind also said he is not convinced the combination offers clinicians a new tool. Brexpiprazole is currently approved as adjunctive treatment of major depressive disorder in adults, treatment of schizophrenia in adults and adolescents aged 13 years or older, and treatment of agitation associated with Alzheimer's dementia. 'We already have sertraline, and we already have brexpiprazole. The prescribing physician can make the decision to progress to the combination or start with it in the patient with PTSD,' Raskind said. Other committee members agreed. Committee members in general felt that in the real world, co-initiation of both drugs may not be the preferred approach. It's more likely that clinicians would opt to start sertraline first, then add brexpiprazole if needed. 'Third-party payers may require that,' Dunn predicted. During the public comment period, Michael Abrams, PhD, MPH, senior health researcher with Public Citizen, said the data supporting the use of this combination for treatment of PTSD is 'weak at best, based on two conflicting phase 3 trials and a questionable post hoc analysis of data from a phase 2 trial,' and he urged the committee and the FDA to reject the combination. The lone 'yes' vote for the brexpiprazole-sertraline combination in PTSD came from the patient advocate on the committee, Laura Block, PharmD, clinical pharmacist (retired), Cary, North Carolina. Block noted that while both of these individual component drugs are on the market, a third-party payer isn't likely to pay without an FDA-approved indication. 'That means that there are those who are going to have difficulty accessing,' Block commented. At the same time, Block said she would not want to offer patients 'destructive false hope,' and whether it is approved, she would like to see either a phase 3 or phase 4 study. Currently, the SSRI sertraline and paroxetine are the only FDA-approved medications for PTSD, and while these medications can be effective, many patients fail to achieve remission or discontinue treatment due to side effects or lack of response. The proposed upfront co-initiation of brexpiprazole with sertraline is a novel treatment paradigm. If approved by the FDA, it would be the first new treatment for PTSD in more than 20 years. The FDA is not required to follow the advice of its advisory committees, but it often does.
Bloomberg
5 days ago
- Health
- Bloomberg
Otsuka, Lundbeck's PTSD Drug Fails to Win US FDA Panel Support
Otsuka Pharmaceutical Co. 's medicine for post-traumatic stress disorder with partner H. Lundbeck A/S failed to win the backing of US regulatory advisers, a major setback in the drugmakers' bid to bring the first new drug for the condition to market in more than two decades. The panel of external advisers to the Food and Drug Administration voted 10-to-1 on Friday that the efficacy of the companies' brexpiprazole tablets marketed under the brand name Rexulti — in combination with sertraline — hadn't been established.
Yahoo
15-07-2025
- Business
- Yahoo
Otsuka to acquire Cantargia's CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in development as a drug candidate for autoimmune diseases. CAN10 targets interleukin-1 receptor accessory protein (IL1RAP) with potent inhibitory effects on pro-inflammatory cytokines within the interleukin 1 (IL-1) superfamily — IL-1, IL-33 and IL-36 — which are associated with various inflammatory or autoimmune diseases. Cantargia will receive a $33m upfront cash payment and up to an additional $580m in milestone payments, along with double-digit tiered earn-out payments from worldwide product sales. The transaction is subject to customary closing conditions and regulatory approval, with expectations set for completion in the third quarter of 2025. Otsuka Pharmaceutical president and representative director Makoto Inoue stated: "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our US subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our US subsidiary Jnana Therapeutics. 'This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients." Otsuka Pharmaceutical will take full responsibility for developing and commercialising CAN10 across the globe. This entails directing all future development activities, seeking regulatory approvals, as well as exclusively managing manufacturing and sales operations worldwide. Otsuka Pharmaceutical also gains access to 3G5, a backup antibody. CAN10 is currently in a Phase I clinical trial. Cantargia interim CEO Damian Marron stated: 'This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune-inflammatory disorders. 'We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world-leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases.' "Otsuka to acquire Cantargia's CAN10 for autoimmune diseases" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
15-07-2025
- Business
- Yahoo
Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical
Cantargia receives an upfront cash payment of USD 33 million. Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments from global product sales. Otsuka Pharmaceutical obtains worldwide rights for the development and commercialization of the CAN10 program. LUND, SE / / July 15, 2025 / Cantargia AB (publ) (Cantargia) (Nasdaq Stockholm:CANTA) today announced that it has entered into an agreement with Japanese healthcare company Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) pursuant to which Otsuka Pharmaceutical will acquire all Cantargia's assets related to its early-clinical stage CAN10 program. Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment and is eligible to up to additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales. The transaction, subject to customary closing conditions and regulatory approval, is expected to close in the third quarter of 2025. Otsuka Pharmaceutical will be fully responsible for the development and commercialization of CAN10 globally. Otsuka Pharmaceutical will direct and perform all future development, apply for regulatory approvals and exclusively carry out manufacturing and sales of the product worldwide. In addition to the CAN10 antibody, Otsuka Pharmaceutical acquires 3G5 [1] as a backup antibody and will also have exclusive first rights of negotiation regarding the next-generation IL-1RAP antibodies to be developed by Cantargia for a period of 2 years. CAN10 is an antibody against IL1RAP designed to potently inhibit the activity of the pro-inflammatory and disease promoting cytokines of the IL-1-super family: IL-1, IL-33 and IL-36. CAN10 is currently being evaluated in an ongoing phase 1 clinical trial. "This is a transformative transaction for Cantargia, and we hope for millions of patients suffering from severe immune inflammatory disorders." said Cantargia's Interim Chief Executive Officer Damian Marron. "We are delighted that the strong potential of our CAN10 anti-IL1RAP antibody has been recognised by Otsuka Pharmaceutical. It demonstrates confidence in the strength of our world leading position in IL1RAP biology and antibodies and will allow us to drive forward our platforms and programs in oncology and other diseases." Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., Ltd., commented, "Otsuka Pharmaceutical is expanding its research and development pipeline in the field of autoimmune diseases by leveraging the antibody drug platform of our U.S. subsidiary, Visterra, and the low-molecular-weight drug discovery platform of our U.S. subsidiary Jnana Therapeutics. This will further expand and accelerate our research and development portfolio targeting various pathways associated with autoimmune diseases, enabling us to contribute to the lives of more patients." [1] 3G5 is a pre-clinical IL1RAP targeting antibody which is similar to CAN10. For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-15 08:45 CEST. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About CAN10The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling of the cytokines of the IL1-super family via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. In preclinical in vivo models of inflammatory diseases, such as systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis, myocarditis and peritonitis, a CAN10 surrogate antibody significantly reduced the development of the disease. A clinical phase 1 study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. About Otsuka PharmaceuticalOtsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit AttachmentsCantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical SOURCE: Cantargia View the original press release on ACCESS Newswire
Medscape
14-07-2025
- Health
- Medscape
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a supplemental new drug application for brexpiprazole (Rexulti, Otsuka Pharmaceutical Co., Ltd.), in combination with sertraline, for the treatment of adults with posttraumatic stress disorder (PTSD). If approved, it would be the first new treatment for PTSD in more than 20 years. 'It is my hope that the FDA does approve this treatment for two related reasons — the data look positive and compelling, and there's a tremendous unmet need in PTSD,' Roger McIntyre, MD, professor of psychiatry and pharmacology and head of the Mood Disorders Psychopharmacology Unit, University of Toronto, Toronto, Ontario, Canada, told Medscape Medical News. What's in the Treatment Toolbox Now? PTSD is a 'common, severe, and nonremitting condition,' McIntyre noted. According to the National Center for PTSD, the condition affects roughly 13 million adults in the US in any given year. This represents about 5% of the adult population. PTSD can develop following exposure to traumatic events such as combat, assault, disasters, or severe accidents. Core symptoms of PTSD include intrusive memories and flashbacks, avoidance behaviors, negative alterations in mood and cognition, and hyperarousal. Currently, the selective serotonin reuptake inhibitors (SSRI), sertraline and paroxetine, are the only FDA-approved medications for PTSD, and while these medications can be effective, many patients fail to achieve remission or discontinue treatment due to side effects or lack of response. Other medications used off-label to treat PTSD — including prazosin, mirtazapine, atypical antipsychotics, and mood stabilizers — have shown variable efficacy. There has not been a new FDA-approved drug for PTSD in over two decades, underscoring the need for better therapeutic options, particularly for patients who do not fully respond to SSRI alone. Why Brexpiprazole Plus Sertraline? Brexpiprazole is an atypical antipsychotic currently approved as adjunctive treatment of major depressive disorder (MDD) in adults; treatment of schizophrenia in adults and adolescents aged 13 years or older; and treatment of agitation associated with Alzheimer's dementia. The combination of brexpiprazole and sertraline could address the limitations of SSRI alone by working synergistically to treat PTSD. Sertraline increases serotonin levels in the brain to improve mood and reduce anxiety. Brexpiprazole has a complex mechanism of action involving multiple neurotransmitter systems, including but not limited to serotonin and dopamine. Together, they may target different aspects of PTSD, potentially leading to a more comprehensive reduction in symptoms. What Do the Phase 3 Data Show? In a pivotal, double-blind, randomized controlled, phase 3 trial, brexpiprazole plus sertraline provided significantly greater relief of PTSD symptoms than sertraline plus placebo. The results were published late last year in JAMA Psychiatry and reported by Medscape Medical News at that time. The trial enrolled 416 adults (mean age, 37 years; 75% women) aged 18-65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-5 ) diagnosis of PTSD and symptoms for at least 6 months prior to screening. At baseline, participants had a mean Clinician Administered PTSD Scale (CAPS-5) for DSM-5 total score of 38.4, indicating moderate to high severity PTSD. The average time from the index traumatic event was 4 years, and three fourths had no prior exposure to PTSD prescription medications. Participants underwent a 1-week placebo run-in period followed by randomization to daily oral brexpiprazole 2-3 mg plus sertraline 150 mg or daily sertraline 150 mg plus placebo for 11 weeks. At week 10, brexpiprazole plus sertraline demonstrated statistically significant greater improvement in the CAPS-5 total score (primary outcome) than sertraline plus placebo (mean change, -19.2 points vs -13.6 points; P < .001). Brexpiprazole plus sertraline also led to statistically significant greater improvement on all key secondary and other efficacy endpoints, both clinician-reported and patient-reported, including measures of anxiety, depression, intrusive symptoms, hyperarousal, and overall functioning. Combining an atypical antipsychotic with an antidepressant for PTSD 'builds on what we've been doing in depression,' Elspeth Ritchie, MD, chair of Psychiatry, MedStar Washington Hospital Center, Washington, DC, noted in an interview with Medscape Medical News . 'We have found that a combination of a low-dose antipsychotic and an antidepressant is helpful for depression, so it makes sense that it will be helpful for PTSD. However, this has been mostly based on clinical decisions, without a heavy research background. Good science is always helpful to support those clinical decisions,' Ritchie told Medscape Medical News . What About Safety? In the phase 3 trial, brexpiprazole plus sertraline had a safety profile consistent with that of brexpiprazole in approved indications. The rate of discontinuation due to adverse events was low (3.9% for brexpiprazole plus sertraline vs 10.2% for sertraline plus placebo), indicating that most participants tolerated the brexpiprazole and sertraline combination treatment, the study team said. In both treatment groups, the only treatment-emergent adverse event (TEAE) with incidence greater than 10% was nausea, a known adverse effect of sertraline treatment. Weight gain was greater in participants receiving the combination. At the last visit, a weight gain of 7% or greater from week 1 was experienced by 8% of participants taking brexpiprazole with the sertraline group and 5% of those taking the sertraline plus placebo. Previous analyses in schizophrenia and MDD show that brexpiprazole is associated with moderate weight gain (+3 to 4 kg over 1 year). The incidence of sedating TEAEs (a concern with some antipsychotics) was generally low, although fatigue (7% vs 4%) and somnolence (5% vs 3%) were more common with brexpiprazole plus sertraline than with sertraline alone. There were no clinically meaningful between-group differences in changes in laboratory test parameters, vital signs, or ECG and participant-reported TEAEs related to suicidality. Potential Concerns As with any new drug application, several questions and issues are likely to be raised by the advisory committee. They could include whether the clinical benefit is substantial enough to warrant approval and how the observed effect sizes compare to existing approved therapies and evidence-based psychotherapies. McIntyre told Medscape Medical News what's particularly noteworthy is that the magnitude of the improvement in PTSD symptoms with brexpiprazole plus sertraline is greater than with sertraline alone. 'That's a very important statement. And this high level of efficacy was consistent on the secondary outcome measures, and the overall tolerability and safety seemed very acceptable,' he said. What's equally important, said McIntyre, is that most people with PTSD have depression and anxiety, and the brexpiprazole plus sertraline combination was more helpful than sertraline alone on the measures of anxiety and depression. 'This is really important, especially in light of the fact that this medication [brexpiprazole] is already approved for adults living with major depressive disorder and inadequate response to antidepressants,' McIntyre said. McIntyre added he suspects some questions the committee may have could relate to the extent to which it's the case that brexpiprazole is effective in PTSD regardless of the antidepressant that is prescribed with it. 'There also will be the inevitable questions about the absence of long-term data which I think will need to be addressed given how chronic and relapse prone this condition is,' McIntyre said. The committee may ask how trauma and PTSD will be screened in primary care and how outcomes related to this therapy will be evaluated in everyday clinical practice, McIntyre said. Overall, McIntyre said brexpiprazole plus sertraline in PTSD is a 'very positive' development for the field. 'PTSD is a terrible condition. It's so darn common, and we just don't have enough treatments for it. The data look good for my perspective. My fingers are crossed for the patients with PTSD and their families,' said McIntyre.
